Evidence map›Paper›PMID 40502063›Full record

ArticlebioRxiv : the preprint server for biology2025

A multi-step immune-competent genetic mouse model reveals phenotypic plasticity in uveal melanoma.

Xiaonan Xu, Xiaoxian Liu, James J Dollar, Xiao Liu, Neel Jasani, Benjamin Posorske, Sathya Neelature Sriramareddy, Vinesh Jarajapu, Jeffim N Kuznetsoff, John Sinard and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Xiaonan XuDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID 0000-0002-7366-580X
Xiaoxian LiuDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
James J DollarBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Xiao LiuDepartment of Ophthalmology and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Neel JasaniDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID 0000-0003-1133-5554
Benjamin PosorskeDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Sathya Neelature SriramareddyDepartment of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID 0000-0001-9189-3956
Vinesh JarajapuDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Jeffim N KuznetsoffBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0002-6197-2642
John SinardDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0001-8739-517X
Richard L BennettDivision of Hematology/Oncology, University of Florida Health Cancer Center, University of Florida, Gainesville, FL, USA.
Jonathan D LichtDivision of Hematology/Oncology, University of Florida Health Cancer Center, University of Florida, Gainesville, FL, USA.
Keiran S M SmalleyDepartment of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
J William HarbourDepartment of Ophthalmology and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-1104-9809
Xiaoqing YuDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Florian A KarrethDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID 0000-0002-2350-9809

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Kathryn Ann O'Donnell · 2010 to 2026
$53.7M
Stem Cell, Organoid and Cell Phenotyping ModuleP30EY030413 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI W MATTHEW PETROLL · 2019 to 2026
$5.9M
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasisR01CA256193 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI HARBOUR, JAMES WILLIAM, LICHT, JONATHAN D. · 2021 to 2025
$3.2M
Investigating epigenetic mechanisms of cancerR50CA293837 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI Richard L Bennett · 2024 to 2026
$528k
NCI NIH HHS P30 CA076292NCI NIH HHS P30 CA142543NCI NIH HHS R01 CA256193NCI NIH HHS R50 CA293837NEI NIH HHS P30 EY030413
6 · The paper itself

Abstract

Uveal melanoma (UM) is a highly aggressive intraocular malignancy with limited therapeutic options for metastatic disease. Existing transgenic UM mouse models inadequately recapitulate human disease progression, while transplant models lack immune competence for studying the tumor immune microenvironment and therapeutic interventions. To address these limitations, we developed a genetically engineered mouse model incorporating stepwise genetic alterations implicated in human UM progression. Spatiotemporally controlled expression of mutant GNAQ

Identifiers

PMID40502063
PMCPMC12157397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.